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Abstract: The impact of increasingly efficient antiretroviral therapy (ART) on survival and general well-being has 
contributed to a “business as usual” attitude to sex among men who have sex with men (MSM). There has been a recent 
marked increase of sexually transmitted infections (STI) including syphilis, LGV and Hepatits C among MSM. STIs 
located in the oral cavity or rectum are asymptomatic in over 80% and 50%, respectively and these sites must be seen as 
important reservoirs. On the other hand severe proctitis may be mistreated as inflammatory bowel disease without 
adequate medical history and testing. Due to the reappearance of syphilis, all genital ulcers, non-itching exanthema and 
severe disease symptoms (e.g. fever, fatigue, lymphadenopathy, hepato-splenomegaly, increased liver enzymes, 
neurological and ophthalmologic symptoms without other explanations) should lead to testing for syphilis. There is a 
marked association between STIs and HIV. Syphilis, LGV and Hepatits C are strongly overrepresented in HIV positive 
MSM, while gonorrhoea, LGV and syphilis increase the HIV susceptibility. Syphilis leads to increased viral load in HIV 
positive. The major risk factors for Hepatitis B are number of sex partners and receptive anal intercourse. High grade 
Human Papilloma Virus (HPV) anal lesions can progress to cancer. There is a 30 fold increase risk for anal cancer among 
MSM, a risk that is doubled in HIV infection, making anal cancer one of the most common non-AIDS tumours. All MSM 
should be offered Hepatitis A and B vaccination and the inclusion of boys in HPV vaccination programs must be 
considered. The aim of this article is to describe asymptomatic and symptomatic bacterial and viral STIs of the oral cavity, 
penis/urethra and rectum and the sexually transmittable viral Hepatitis and HIV in MSM and to inspire the medical 
establishment to adhere to testing guidelines in this group. This article is built on a review of published findings, the 
presentation of own data on Gonorrhoea and chlamydia and our own experience in treating all STIs including HIV in 
MSM since 1982 at a Gay Men’s Health Clinic (Venhälsan) at Stockholm South General Hospital, Sweden. 
INTRODUCTION 
 This article will focus on the unique social, 
microbiological and medical aspects of sexually transmitted 
infections (STI) in men who have sex with men (MSM). 
This is a complex area requiring expert knowledge and 
frequently a multidisciplinary approach. 
 Firstly, despite 40 years of gay liberation, the patient may 
not spontaneously present himself as an MSM to the 
caregiver. A sexual history should always be taken with 
great sensitivity, with an open and unprejudiced mind. The 
patient should be able to speak openly and in some detail 
about his sexual activities, confident the care provider will 
be non-judgemental. If good contact is not established and 
communication between the doctor and patient is 
insufficient, medically important information might be 
withheld. 
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 Secondly, many STIs affecting the mouth or the anal 
region are prone to be asymptomatic and persistent. Without 
testing for the right microbes in relevant locations, infections 
will be missed. To illustrate the high prevalence of STIs in 
asymptomatic MSM, for example, 7% of Boston MSM who 
reported having high risk sex in the preceding 3 months 
tested positive for at least one STI in the mouth, urethra or 
anus [1]. It is, however, notable that this study did not test 
for rectal and oro-pharyngeal Chlamydia trachomatis. Had 
such tests been included the prevalence might have been 
significantly higher [1]. Over half of STIs will be missed if 
only uro-genital testing is performed [2]. In another study of 
an unselected series of consecutive MSM attending Genito 
Urinary Medicine (GUM) clinics in the UK for sexual health 
screening, the prevalence of non-Lymfogranuloma venereum 
(LGV) Chlamydia trachomatis was 3,3% in the urethra and 
7,0% in the rectum and the prevalence of LGV was 0,04% 
and 0,9%, respectively [3]. 
 Thirdly, many sexual activities engaged in by MSM have 
implications for the STI panorama they are likely to present 
with. Unprotected anal intercourse is an especially effective 
way of transmitting pathogens like Hepatitis B and HIV. 
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Another consequence of unprotected anal sex is the 
increased risk of human papilloma virus (HPV) induced anal 
cancer among MSM, a risk that is even doubled in 
individuals co-infected with HIV [4-6]. Oro-anal contacts 
facilitate the transmission of Hepatitis A, Entamoeba 
histolytica and other intestinal infections. Furthermore, more 
advanced sexual practices such as fisting and the use of sex 
toys seem to be risk factors for blood-blood transmitted 
pathogens such as Hepatitis C as well as for rectal-to-rectal 
STI transmission [3]. 
 Finally, the high and increasing prevalence of long-
standing and well-treated HIV infection among MSM 
contributes to a continuously changing epidemiology, 
exemplified by the increase in syphilis since 1999 [7-11], the 
recent reappearance of LGV (variant L2b) [12] and the 
increase in sexually transmitted Hepatitis C [13]. 
 After the initial, sexually paralysing AIDS shock in the 
early 1980’s there was a marked decrease of STIs for over 15 
years among MSM [14]. However, when the impact of 
protease-inhibitor based antiretroviral therapy (ART) on 
survival and general well-being became obvious in 1997-
1998, sexual risk-taking gradually increased among MSM. 
The emergence of increasingly efficient ART combinations 
with improving long-term safety and simplicity resulting in 
an undetectable viral load in the overwhelming majority of 
treated subjects together with a media-silence regarding HIV 
have resulted in a “business as usual” attitude to sex. The 
optimally treated HIV patient’s sense of wellbeing and their 
belief of being less infectious have also had an impact. 
However, the statement that patients on effective ART who 
are free of any other STI cannot transmit HIV through sex 
has been questioned [15]. Other developments facilitating 
the spread of all STIs include the eroticisation of “bare-
backing” and the exchange of sperm among many HIV 
positive MSM, encouraged by numerous internet sites 
aiming at so called “sero-sorting” and “poz-parties”. 
Obviously, less condom use and an increased number of 
sexual encounters increase the transmission of other STIs 
[16]. 
 The aim of this article is to focus on some aspects of 
asymptomatic as well as symptomatic bacterial and viral 
STIs of the oral cavity, penis/urethra and rectum, the 
sexually transmittable viral Hepatitis and HIV in MSM and 
to discuss testing guidelines. This article is built on a review 
of published findings, own original data regarding 
Gonorrhoea and chlamydia and our own experience in 
treating MSM with all forms of STIs including HIV since 
1982 at a Gay Men’s Health Clinic (Venhälsan) at 
Stockholm South General Hospital, Sweden. Venhälsan 
started in 1982 as a response to the international reports of 
AIDS and other STIs among MSM with the ambition to 
reach as many MSM as possible and offer STI-testing and 
counselling, which since 1985 also included HIV [17]. 
Venhälsan cares today for 1000 HIV positive patients, of 
whom 80% are MSM and have approximately 7000 annual 
visits for STI/HIV testing. 
MATERIALS & METHODS 
 All patients presenting at Venhälsan are offered oro-
pharyngeal, urethral/urin and anorectal testing for 
Gonorrhoea and chlamydia. We have revised all the files of 
patients with positive Gonorrhoea and chlamydia results 
during 2007 and 2008. All patients are MSM. 
 In addition a review of the literature on STIs in MSM has 
been performed and our results are discussed in relation to 
American and European published reports. 
Results from Venhälsan 
 Two hundred and thirty six individuals tested positive for 
Gonorrhoea, 17% had a known HIV-infection and in 5% 
HIV was diagnosed at the time of Gonorrhoea (Table 1a). 
The median age was 31 years. Symptoms were noted only in 
32%, 13% and 96% of the patients with ano-rectal, oro-
pharyngeal and urethral Gonorrhoea, respectively (Table 
1b). Signs/symptoms of proctitis were not more common in 
HIV-positive as compared to HIV-negative MSM (Table 1c). 
Newly diagnosed HIV-infection occurred in 8% and 3% of 
the patients with ano-rectal and urethral Gonorrhoea, 
respectively, but not in any of the patients with oro-
pharyngeal Gonorrhoea (Table 1b). Only 4% and 15% of 
patients with ano-rectal Gonorrhoea with and without 
signs/symptoms of proctitis, respectively, were positive in 
the urethral Gonorrhoea culture (Table 1c). 
 Four hundred and thirty one tested positive for 
chlamydia, 24% had a known HIV-infection and in 4% HIV 
was diagnosed at the time of chlamydia (Table 2a). The 
median age was 34 years. Symptoms were noted only in 
34%, 16% and 51% of the patients with ano-rectal, oro-
pharyngeal and urine chlamydia, respectively (Table 2b). Of 
the patients with rectal chlamydia 17(6%) had anal 
condylomata. Signs/symptoms of proctitis were more 
common in HIV-positive as compared to HIV-negative 
MSM (43/74 (58%) vs 51/199 (26%); p<0,001 (Fisher’s 
exact test)). Of HIV-positive and HIV-negative patients with 
signs/symptoms of proctitis and positive Chlamydia test 30% 
and 4%, respectively had LGV (Table 2c). Newly diagnosed 
HIV-infection occurred in 5%, 2% and 2% of the patients 
with ano-rectal, oro-pharyngeal and urine chlamydia, 
respectively (Table 2b). Only 6% and 14% of patients with 
ano-rectal chlamydia with and without signs/symptoms of 
proctitis, respectively, were positive for chlamydia in the 
urine (Table 2c). Contact tracing was the most common 
reason for the visit in patients with oro-pharyngeal and ano-
rectal Gonorrhoea and chlamydia (Tables 1b, 1c, 2b and 2c). 
Localized Asymptomatic STIs 
 Gonorrhoea has been shown to be transmitted bi-
directionally through oro-penile sex [18] and the same seems 
true for chlamydia [19]. Gonorrhoea and chlamydia usually 
cause no symptoms in the oral cavity and oro-pharyngeal 
symptoms are not predictive of Gonorrhoea/chlamydia, 
making this site an ideal and frequently overlooked STI 
reservoir. In one study only 18,2% and 16,7% of the cases 
with oro-pharyngeal Gonorrhoea and chlamydia, 
respectively, would have been identified on symptom-lead 
testing [20]. We found 87% and 84% of MSM with oro-
pharyngeal Gonorrhoea and chlamydia, respectively, to be 
asymptomatic and 51% and 43% of the patients with positive 
oro-pharyngeal tests, respectively, were only positive in the 
mouth (Tables 1b and 2b). Syphilitic ulcers are probably 
also often overlooked in the oral and ano-rectal sites, 
especially as they can be painless. In our practice only 9% of 
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primary syphilitic lesions are located orally and 23% ano-
rectally [21]. Overall ano-rectal symptoms do not differ 
between men with and without ano-rectal gonorrhoea/non-
LGV chlamydia [22]. However, heavy anal discharge and 
pain was associated to ano-rectal Gonorrhoea in one study 
[22]. Patients with ano-rectal Gonorrhoea/non-LGV 
chlamydia are more likely to be asymptomatic than those 
with urethral infections [20, 23, 24]. Rectal Gonorrhoea is 
reported to be asymptomatic in 50-68% and rectal non-LGV 
chlamydia in 52-86% [3, 7, 19, 24-26], Tables 1b and 2b. 
We found 55% of MSM with rectal Gonorrhoea to have 
normal anoscopy (Table 1b). Most oro-pharyngeal and ano-
rectal Gonorrhoea and chlamydia would go undiagnosed and 
untreated without testing in these sites [2, 26, 27], for 
example we found that 67% and 82%, respectively, of the 
patients with positive ano-rectal samples were positive only 
in this site (Tabled 1b and 2b). Routine testing for oro-
pharyngeal and asymptomatic ano-rectal STI:s in MSM in 
different settings has revealed a Gonorrhoea prevalence of 
1,7-9,2% and 5,0-6,9%, respectively, and a chlamydia 
prevalence of 1,2-1,7% and 4,7-8,0%, respectively [1, 7, 18-
20, 28, 29]. Urethral chlamydia, now common in MSM with 
a prevalence of 6% in the US [30], is asymptomatic in 42-
50% of the cases [3] (Table 2b). A positive urine/urethral 
chlamydia test is found in only 8-15% of MSM with 
asymptomatic rectal chlamydia [26] (Table 2c). 
 We found an overrepresentation of oro-pharyngeal 
chlamydia and coexisting oro-pharyngeal and rectal 
chlamydia among MSM being contact traced/partner notified 
for chlamydia, high lightening the importance of 
asymptomatic oral and rectal chlamydia reservoirs [19]. 
Rectal Gonorrhoea and chlamydia often co-exist, 6,5-13,4% 
of patients with rectal chlamydia also had Gonorrhoea [19, 
26] (Table 2b), while 17,8% of patients with rectal 
Gonorrhoea also had chlamydia (Table 1b). 
 Although LGV often presents with severe proctitis, 
asymptomatic ano-rectal LGV does occur, the reported 
frequency varies considerably from 0% in Canada, 5-17% in 
London and 12-13% in Stockholm to the majority of cases in 
the Netherlands [3, 19, 26, 28, 31, 32] (Table 2c). 
Localized Symptomatic STIs 
Oro-Pharyngeal 
 Of patients with oro-pharyngeal Gonorrhoea and chlamydia, 
10-13% and 16% reported pharyngitis and/or tonsillitis [33] 
(Tables 1b and 2b). Oro-pharyngeal Gonorrhoea is more 
difficult to eradicate than ano-genital with approximately 9-10% 
treatment failures on single dose cefixime or ceftriaxone – a 
further contributing factor to a reservoir for continuing 
transmission [27, 34]. Treatment with single dose cefixime in 
combination with 1 g azithromycin has improved efficacy and 
been reported, in some studies with small numbers of patients, 
to result in 100% negative control cultures [34]. 
 Cervical lymphadenopathy related to oro-pharyngeal LGV 
has been reported and might become an increasing problem 
[35]. 
Penile 
 Urethral Gonorrhoea is usually symptomatic and is rare 
in asymptomatic men [1, 20] (Table 1b). Symptoms of 
gonococcal urethritis include various degrees of urinal 
pain/itching and mucopurulent discharge. Urethral 
chlamydia, in contrast, only causes symptoms in 32-69% [3, 
19, 26] (Table 2b). The symptoms of chlamydia infection are 
usually mild with a watery discharge. Chlamydial/gonoco-
ccal epididymitis or prostatitis are rarely seen in our patient 
cohort, possibly because such patients are acutely ill and 
tend to seek the emergency ward rather than an STI clinic. 
LGV may cause genital ulcers and urethral infection with 
inguinal adenopathy and should always, together with 
Herpes simplex and primary syphilis, be a differential 
diagnosis when evaluating genital ulcers [36]. Oral sex may 
lead to oro-penile transmission of various respiratory 
pathogens such as Moraxella, Streptococci spp and 
Haemophilis parainfluenzae [37, 38] and unprotected anal 
sex might cause E. coli urethritis. Although not extensively 
studied, urethritis caused by Mycoplasma genitalium, does 
not seem to be overrepresented in MSM, probably since it is 
not transmitted by oral sex [39]. 
Ano-Rectal 
 Symptoms of proctitis are: pain, purulent and/or 
haemorrhagic discharge, tenesmus, irritation, itching, 
diarrhoea and/or constipation [40]. It is not uncommon that 
patients with a severe sexually acquired rectal infection like 
LGV have symptoms suggestive of Crohn´s disease [41]. 
They may initially present at a gastroenterology or colorectal 
department and receive treatment for inflammatory bowel 
disease [42, 43] (Table 1b). Even in the pre-AIDS 1970’s the 
frequency of ano-rectal disease in MSM received attention 
and was given the misleading term “gay Bowel Syndrome” 
[44]. This represented a mixture of intestinal infections like 
amoebiasis, shigellosis, proctologic problems like peri-rectal 
abscesses, fissures, haemorrhoids, fistulas, rectal trauma, 
itching and dyspareunia and STIs. Infectious proctitis is 
more common than non-infectious with common causes 
including Gonorrhoea, chlamydia, syphilis and Herpes 
simplex [40]. In a series of 125 MSM with symptomatic 
proctitis in the Netherlands 26% had LGV, 18% Gonorrhoea 
and 24% non-LGV chlamydia [31]. For details about clinical 
features, diagnostic tests and management of proctitis the 
reader is referred to the 2007 updated European Guidelines 
(IUSTI/WHO) on the management of proctitis, proctocolites 
and enteritis caused by sexually transmitted pathogens [45]. 
It is recommended to start treatment at least covering 
Gonorrhoea, LGV and Herpes in severe cases [40]. 
Ano-Rectal Herpes Simplex 
 Acute Herpes simplex proctitis may cause fever, and in 
addition to the symptoms described above difficulty in 
urinating, sacral paresthesia, inguinal lymphadenopathy, 
severe ano-rectal pain, and peri- and intra-anal ulcerations, 
especially during the first episode of HSV-2. HSV-2 was 
detected in 23% of MSM with proctitis in one early study 
[46]. 
Ano-Rectal Mycoplasma Genitalium 
 There are only a few studies of ano-rectal Mycoplasma 
genitalium, but 5,4% of rectal specimens in a cross-sectional 
pilot study in an STI clinic in San Fransisco were positive 
and there was a weak association to rectal symptoms and 
proctitis [47]. Interestingly, in the multivariate analysis only 
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positive HIV status was associated with Mycoplasma 
genitalium infection [47]. 
Ano-Rectal Syphilis 
 It is important to remember that syphilis may cause 
severe very painful ulcerative proctitis, sometimes with an 
anorectal mass. 
Ano-Rectal Gonorrhoea 
 Symptoms of proctitis were significantly more common 
in rectal Gonorrhoea than in isolated rectal non-LGV 
chlamydia infection in one study [48]. In our cohort of 100 
patients with rectal Gonorrhoea, 32% presented with ano-
rectal symptoms and 45% had an anoscopy verified proctitis 
(Table 1b). Two patients had anal abscesses with growth of 
gonococci and one patient had been treated for inflammatory 
proctitis at the gastroenterology department prior the correct 
diagnosis being made (Table 1b). 
Ano-Rectal Non-LGV Chlamydia and LGV 
 Both non-LGV chlamydia and LGV can cause severe 
proctitis, however, non-LGV infections are usually milder 
[41, 43]. As early as 1981-83 LGV was associated with 
severe proctitis [41], one case presenting with massive rectal 
bleeding [42]. Although urethral/penile LGV presenting with 
ulcers has been reported, severe painful ulcerative purulent 
proctitis with rectal discharge, urge to defecate, tenesmus 
and the passage of blood are frequently the dominating 
symptoms of LGV [49]. Untreated chronic LGV may lead to 
abscesses that may rupture, severe perianal fistulas, genital 
elephantiasis, strictures and fibroses and may resemble 
Crohn’s disease, although the appearance is non-specific 
[49]. The local lymph nodes are involved with pain, 
swelling, necrosis and perforation [12, 49]. Since the 
recognition of the ongoing outbreak of LGV among MSM in 
Rotterdam, Holland [50], infections have been reported from 
many parts of Europe, North America and Australia [12, 31, 
49] and LGV has become endemic among MSM in some 
areas of the UK [3]. From our experiences 14-16% of 
patients with symptomatic rectal chlamydia had LGV, a 
figure increasing to 30% in the case of HIV-positive patients 
[19] (Table 2c). The majority of LGV patients in the current 
outbreak are HIV positive, and often have other STIs at the 
LGV diagnosis [12, 19]. A high proportion of HIV negative 
MSM with LGV become HIV positive soon after the LGV 
diagnosis [51]. In a Dutch study comparing proctitis of 
different causes, LGV patients were older, had more often a 
history of syphilis and Hepatitis C and 78% were HIV-
positive [31]. The use of sex toys, enemas, having sex at sex 
parties and sex with HIV positive partners came out as 
significant LGV risk factors in multiple logistic regression 
[31]. In a case-control study of symptomatic rectal infections 
Table 1a. All Gonorrhoea Diagnosed at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%) 
 
n 
Positive at More 
 Than One Site  
n (%) 
Age 
(Years: Median and Range) 
Also Diagnosed with  
Chlamydia  
n (%) 
Known HIV  
Infection  
n (%) 
Newly Diagnosed HIV 
Infection  
n (%) 
236 47 (20) 31 (17-67) 42 (18) 39 (17) 11 (5) 
 
Table 1b. Gonorrhoea in Different Sites Diagnosed at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%) 
 
Site of Positive 
Gonorrhoea  
Culture 
n 
Only One Site 
n (%) 
Testing Due to 
Contact Tracing 
n (%) 
Symptoms in the 
Positive Site 
n (%) 
Known HIV 
Infection 
n (%) 
Newly Diagnosed  
HIV Infection 
n (%) 
Pharyngeal 87 44 (51) 29 (33) 11 (13) 6 (7) 0 (0) 
Urethral 103 79 (77) 5 (5) 99 (96) 20 (20) 3 (3) 
Anorectal 100 67 (67) 43 (43) 32 (32) 
*
 19 (19) 8 (8) 
*) 45 (45%) had pathological anoscopy. Two patients had rectal abscesses with growth of gonococci, two had rectal fissures and one was admitted to the gastroenterology clinic and 
received treatment for inflammatory bowel disease. 
 
Table 1c. Ano-Rectal Gonorrhoea at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%) 
 
Positive Ano-Rectal 
Gonorrhoea (n=100) 
n (%) 
Also Positive in 
Urethra 
n (%) 
Testing Due to 
Contact Tracing 
n (%) 
Ano-Rectal 
Chlamydia 
n (%) 
Known HIV 
Infection 
n (%) 
Newly Diagnosed 
HIV Infection 
n (%) 
Sign/symptom of proctitis; 
HIV-positive and negative  
45 (45) 2 (4) 9 (20) 9 (20) 9 (20) 4 (9) 
Sign/symptom of proctitis; 
HIV-positive  
13 (13) 0 (0) 2 (15) 4 (31) 9 (69) 4 (31) 
Sign/symptom of proctitis; 
HIV-negative  
32 (32) 2 (6) 7 (22) 5 (16) 0 0 
No sign/symptom of proctitis; 
HIV-positive and negative 
55 (55) 8 (15) 34 (62) 10 (18) 10 (18) 4 (7) 
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in London LGV was associated with rectal discharge, higher 
age, fisting, HIV infection and less protected anal intercourse 
[43]. LGV treatment consists of doxycycline 100 mg twice 
daily for 21 days and should be initiated on suspicion in 
chlamydia positive proctitis, especially in HIV-positive 
patients, since confirmation might be delayed [40, 43]. 
Syphilis 
 Untreated syphilis is highly contagious during the first 2 
years (early syphilis). The main route of transmission is 
unprotected oral and anal intercourse. Since unprotected oral 
sex, considered less risky regarding HIV transmission, is 
widely practised among both HIV negative and positive 
MSM, it has been considered the most important manner of 
transmission [9, 52]. High numbers of anonymous contacts 
and delays in diagnosis lead to an increased transmission rate 
and great difficulties in contact tracing [9]. During the 
1980’s and early 90’s there was a marked decrease of 
syphilis in Western Europe [53, 54]. Experience of syphilis 
infection both among doctors and MSM was lacking at the 
beginning of the current outbreaks. All genital ulcers, non-
itching exanthema and severe disease symptoms (e.g. fever, 
fatigue, lymphadenopathy, hepato-splenomegaly, increased 
liver enzymes, neurological and ophtalmological symptoms) 
without an obvious explanation should lead to testing for 
syphilis, especially in MSM, regardless of HIV status. 
During the last 10 years there have been numerous outbreaks 
of syphilis among MSM [7], starting in Dublin, Oslo and 
cities in the UK, to be followed in all major cities in Europe 
and North America, as well as other parts of the world [7, 9, 
10, 55, 56]. There is a strong association between syphilis 
and other STIs, especially HIV [7-11]. The HIV prevalence 
among MSM diagnosed with syphilis in Europe is reported 
between 14-59% [7, 21]. HIV infection seems to increase the 
susceptibility for syphilis and co-infection with syphilis was 
the greatest risk factor for a new HIV infection in one study 
[57]. Between 2-5% are diagnosed with syphilis and HIV at 
the same time [7, 21]. We have found that 10% of HIV 
negative men with syphilis 1999-2009 have become HIV 
infected after their syphilis infection and that 25% of newly 
diagnosed HIV positive men have had syphilis [21]. 
Untreated syphilis in HIV positive subjects leads to 
increased viral load and decreased CD4 levels [58] and is 
reported to progress more rapidly with increased risk for 
early cerebral/ocular involvement, especially if the CD4 
count is low and the HIV infection is untreated [59]. There is 
an increased risk to infect sex partners with HIV [11, 58, 60]. 
In 10-13% of patients gonorrhoea and/or chlamydia is also 
diagnosed at the same time as syphilis [9, 21] and of our 
patients with Gonorrhoea and chlamydia 4 and 3%, 
respectively, were simultaneously diagnosed with syphilis 
(data not shown). Staging of the syphilis infection in our 
cohort showed 52% to have primary syphilis, usually with a 
Table 2a. All Chlamydia Diagnosed at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%). 
 
n 
Positive at More 
than One Site 
n (%) 
Age 
(Years; Median; Range) 
Also Diagnosed with 
Gonorrhoea 
n (%) 
Known HIV 
Infection 
n (%) 
Newly Diagnosed 
HIV Infection 
n (%) 
431 50 (12) 34 (19-74) 45 (10) 103 (24) 16 (4) 
 
Table 2b. Chlamydia in Different Sites Diagnosed at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%) 
 
Site of Positive 
Chlamydia  
n 
Only One Site 
n (%) 
Testing Due to 
Contact Tracing 
n (%) 
Symptoms in the 
Positive Site 
n (%) 
Known HIV 
Infection 
n (%) 
Newly Diagnosed 
HIV Infection 
n (%) 
Pharyngeal 49 21 (43) 24 (49) 8 (16) 6 (12) 1 (2) 
Urethral 168 138 (82) 44 (26) 85 (51) 26 (15) 3 (2) 
Anorectal 273 224 (82) 86 (32) 94 (34)  60 (22) 14 (5) 
 
Table 2c. All Ano-Rectal Chlamydia at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%); GC: Gonorrhoea 
 
Positive Ano-Rectal  
Chlamydia (n=273) 
n (%) 
Also Positive in 
Urine/Urethra 
n (%) 
Testing Due to 
Contact Tracing 
n (%) 
LGV 
n (%) 
Ano-Rectal 
GC 
n (%) 
Known HIV 
Infection 
n (%) 
Newly Diagnosed 
HIV Infection 
n (%) 
Sign/symptom of proctitis; 
HIV-positive and negative 
94 (34) 6 (6) 24 (26) 15 (16)  10 (11) 38 (40) 5 (5) 
Sign/symptom of proctitis; 
HIV-positive  
43 (58) 2 (5) 7 (16) 13 (30) 5 (12) 38 (88) 5 (12) 
Sign/symptom of proctitis; 
HIV-negative  
51 (26) 4 (8) 17 (33) 2 (4) 5 (10) 0 0 
No sign/symptom of proctitis; 
HIV-positive and negative 
179 (66) 25 (14) 62 (35) 2 (1) 12 (7) 22 (12) 9 (5) 
STI in MSM The Open Infectious Diseases Journal, 2009, Volume 3    123 
penile primary lesion (68%), 22% to have secondary syphilis 
while 26% were in latency [21]. The median age at syphilis 
diagnosis is higher than for gonorrhoea/chlamydia and 
similar to the median age at HIV-diagnosis in Sweden [21]. 
Relapses/re-infections by syphilis are common [9, 21], 
especially in HIV positive individuals [59]. Non-treponemal 
antigen tests like the rapid regain test (RPR) and the venereal 
disease research laboratory (VDRL) test are used to rapidly 
detect symptomatic syphilis, and should always be 
confirmed by a treponemal antigen test like TPPA [61]. 
Screening serology (eg VDRL, TPPA) can be negative up to 
one month after the presentation of a chancre and up to three 
months after being infected [61]. Specific tests, e. g. tests 
based on IgM-antibodies or PCR can become positive 
earlier, but are expensive and rarely included in routine 
clinical strategies. In clinical practice treatment “on clinical 
suspicion” is often preferred to the “wait for sero-
conversion” strategy in sero-negative patients with a history 
indicative of syphilis. 
 Neurosyphilis is diagnosed by liquor analysis. HIV co-
infection and a high VDRL or RPR titre should raise the 
suspicion of neurosyphilis [61, 62]. Treatment should be 
handled by experienced clinics, usually at dermato-
venereological or infectious disease units and follow 
international guidelines [61]. Syphilis treatment is the same 
regardless of HIV status. 
Hepatitis A 
 Hepatits A (HAV) is easily transmitted through sexual 
practices involving fecal-oral exposure [63]. Although HAV 
never becomes chronic, HAV more often causes significant 
clinical disease than hepatitis B. There have been several 
outbreaks of HAV in MSM e.g. in 1979-1980 in Stockholm 
[64]. In 1982, prior to any HAV vaccination, we found 26% 
of the attending MSM to be anti-HAV positive [17]. 
Although effective vaccination with formalin killed HAV 
(preferably administered as two doses with 6 months 
interval) has been generally available at a low cost for many 
years, only half of MSM in UK are anti-HAV IgG positive 
[65]. The relative failure in offering MSM HAV-vaccination 
has resulted in continuing regular HAV outbreaks, e.g. in 
Copenhagen 2004 where casual sauna sex appeared to be a 
risk factor [66]. As the general immunity to HAV decreases 
in the western community, all MSM not living in 
monogamous relationships, are advised to undergo HAV 
immunization [63]. 
Hepatitis B 
 In industrialized countries most cases of hepatitis B virus 
(HBV) infection are acquired through sexual intercourse or 
through needle sharing by intravenous drug users (IVDU) 
[63]. The major risk factors for HBV infection in MSM 
include receptive anal intercourse and the number of sex 
partners [67]. The initial epidemiological matching of HBV 
and AIDS generated a hypothesis of HBV being a cofactor 
for AIDS [68]. HBV infection is prevalent and most often 
asymptomatic among MSM but may lead to significant 
morbidity and death. The prevalence of positive HBV 
surface antigen (HBsAg) and antibodies to the HBV core 
antigen (anti-HBc) has been found to be 1-6% and 12-68%, 
respectively, in MSM in various materials during the last 30 
years [17, 48, 63, 69]. During the last two decades the 
proportion of newly HIV diagnosed MSM at our clinic with 
positive HBsAg and positive anti-HBc has been 3% and 
38%, respectively (own unpublished data). Chronic HBV 
infection is related to 60-90% of all hepatocellular 
carcinomas in adults, a preventable disease as first evidenced 
by the universal vaccination program in Taiwan [70]. 
Although an effective recombinant vaccine has been in 
existence for 25 years, vaccination rates among MSM are 
still low [71], although rising [48]. Routine HBV 
immunization with 3 injections, which in most countries has 
been introduced as universal childhood vaccination, is also 
recommended for all MSM and for persons evaluated or 
treated for STIs [63]. Modern antiviral therapy in individuals 
who develop chronic infection and do not clear the virus 
themselves include tenofovir, which is highly effective in 
promoting a durable and sustained suppression of the virus, 
increasing survival and quality of life and hopefully 
preventing end stage liver disease and hepatocellular cancer. 
Such treatment aims at undetectable HBV DNA and is 
comparable to HIV-treatment [72]. 
Hepatits C 
 Although needle sharing among IVDU is considered the 
main way of transmission, a proportion of HCV infected 
individuals are not IVDU, many of whom may have been 
sexually infected. HCV infection causes no symptoms during 
the first couple of decades; the only signs being raised liver 
enzymes. Since 2000 there has been a marked rise in 
hepatitis C (HCV) infection in HIV-positive MSM in 
different countries with circulating clusters of limited 
genotypes (1a, 4d, 3a, 1b and 2b/c), suggesting an 
“international transmission network” [73]. Sexual spread of 
HCV seems to coincide with syphilis and LGV in HIV 
positive MSM [74]. In France, for example, the prevalence 
of HCV among HIV-positive MSM was 3,1% in 2004 [75] 
and in the UK an annual incidence rise of 20% among HIV 
positive MSM was found between 2002 and 2006 [76], 
whilst the prevalence in HIV-positive MSM in Amsterdam 
increased from 15% to 21% between 2007 and 2008 [13]. It 
is important to be aware of the persistent high-risk behaviour 
in a subgroup of HIV positive MSM and perform intense 
counselling as well as screening for STIs including HCV in 
this group. Finding all HCV infected individuals is crucial, 
since today’s and tomorrow’s treatment options are rapidly 
making HCV a potentially curable disease [77]. We have 
neither ourselves nor in the literature found an 
overrepresentation of HCV in HIV negative MSM. Although 
this could change rapidly, for the moment there are no data 
indicating spread of HCV to HIV negative MSM through sex 
[76]. 
Human Papilloma Virus (HPV) 
 HPV is easily transmittable through all intimate contacts. 
International studies show a high prevalence of HPV in 
MSM in general and in HIV positive MSM in particular. The 
basal cell of the anal epithelium is highly susceptible to HPV 
infection. Approximately 15 types of HPV are classified as 
"high risk" (e.g. HPV 16 and 18) due to their association 
with cervical cancer, other ano-genital cancers, and tonsillar 
squamous cell carcinoma [78, 79]. In addition, there are also 
a number of "low risk" HPV types e.g. HPV 6 and 11 related 
to condylomata acuminata (genital warts). Despite the high 
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prevalence of persistent HPV infection, the progression to 
pre-cancerous dysplasia tends to be relatively rare and slow, 
thus allowing for intervention over long time [78]. In a 
sample of MSM 85% had “low-risk” and 77% “high-risk” 
anal HPV, with a mean of 4.2 concurrent HPV types in HIV 
negative and 7.1 in HIV positive men. “High-risk” HPVs 
were associated with anal condyloma in HIV negative and 
anal bleeding in HIV positive men [80]. In another sample 
from San Francisco, 34% of the HIV negative MSM and 
72% of the HIV positive MSM carried “high-risk” HPV 
[81]. Furthermore, a longitudinal Canadian study found anal 
HPV in almost 98% of HIV-positive MSM, with a mean of 
five types simultaneously, most frequently HPV 16 (38%) 
and HPV 6 (35%) with the lowest clearance rate seen for 
HPV 16 [82]. 
Anal Cancer 
 Cervical and anal cancers are similar in so far as they 
occur in the transition zone between columnar and squamous 
epithelium. There is increasing evidence that high-grade 
HPV-related anal lesions can progress to cancer over time 
[83]. A recent review comprising 37 international studies 
found an HPV 16/18 prevalence of 72% in invasive anal 
cancer, 69% in high-grade and 27% in low-grade anal 
squamous intraepithelial lesions [84]. Cross-sectional studies 
have found prevalence’s of anal cancer precursor changes of 
5-35% in HIV negative and 15-59% in HIV positive MSM 
[81, 85, 86]. A French study found HPV related lesions in 
37% of HIV infected MSM, of which over half hade 
histologically verified dysplasia [87]. Risk factors for 
squamous intraepithelial lesions in HIV negative and anal 
cancer in HIV positive MSM include older age at first 
receptive anal intercourse, high frequency of unprotected 
receptive anal intercourse, use of injection drugs, anal HPV 
infection and higher number of concurrent HPV types [85, 
87]. Other contributing factors include low CD4 cell count, 
and cigarette smoking [83, 88]. The incidence of anal cancer 
is increasing and is particularly high in MSM with the 
highest incidence in HIV infected MSM [78]. The relative 
risk for anal cancer in HPV infected individuals as compared 
to the general population is 31.2 in MSM and up to 60 in 
HIV positive MSM and actually both are higher than for 
cervical cancer [4-6]. HIV infected patients are at higher risk 
of viral persistence, multiple HPV genotypes (mainly HPV-
16), squamous intraepithelial cancer precursor lesions and 
progress to invasive cancers [89]. The longer survival of 
HIV-positive subjects allows progression of HPV pre-
neoplastic disease to cancer, whereas immunologic 
improvement does not affect the incidence of HPV-
infections, which is more related to risk behaviour. Anal 
cancer is one of the most common non-AIDS defining 
tumours in HIV positive MSM and is increasing despite 
effective ART [83]. In our own clinical cohort of 202 HIV 
infected patients, of whom 188 are MSM who started ART 
in 1996, eight (4%) have developed anal cancer to date 
(Bratt, Eriksson et al. unpublished data). 
HPV-Vaccines 
 In 2006, new vaccines against HPV 16 and 18 with or 
without effect also against two “low-risk” HPVs were 
licensed in the US and Europe. The vaccine’s preventive 
effect can only be fully achieved if given prior to HPV 
exposure and if followed up with booster doses. Recently, 
vaccination programs for girls have been implemented in 
several European countries. However, the models that 
underlie the implementation of those vaccination programs 
do not take into account non-cervical HPV related cancers 
and do not consider other sexual behaviour than 
conventional heterosexual intercourse [90]. A review and a 
meta-analysis suggest that HPV vaccination could prevent 
80% of anal carcinoma if both sexes were included in 
vaccination programs [84, 91]. Although sparsely investi-gated 
among MSM, studies indicate lack of knowledge about HPV 
and its relation to condyloma and anal cancer in general [92, 
93] and about HPV vaccines in particular [94]. We feel that 
there is an urgent need to investigate the cancer preventive 
effect of HPV vaccines in MSM and the feasibility of 
including both men and women in vaccine programs. 
HIV 
 STIs are markers for high risk sex through which HIV 
can be transmitted. STIs also facilitate transmission and 
acquisition of HIV through several direct biological 
mechanisms, including boosting genital HIV shedding, 
increasing recruitment of “ready to be infected” lymphocytes 
and macrophages and disrupting the mucosal barrier [57, 
60]. Gonorrhoea, syphilis and to a lesser extent chlamydia 
are associated with higher amounts of HIV in genital 
secretions in co-infected subjects [95]. To increase the 
knowledge about actual risk factors for becoming HIV 
positive detailed studies of the recently HIV infected MSM 
are crucial. Recently acquired HIV is associated with having 
had an STI the last years and often having a concurrent STI, 
especially syphilis and rectal and urethral Gonorrhoea [96-
98]. In one study 23% of newly HIV diagnosed MSM were 
concomitantly co-infected with another STI, with syphilis as 
the greatest risk (OR=11,1 (95% CI:7,7-15,8)) [57]. In our 
own clinic this figure is 29%, while 41% had had an STI 
during the last 2 years [99]. Gonorrhoea and chlamydia were 
found in 26% and 19%, respectively, among newly HIV-
diagnosed MSM in San Francisco [100]. Concurrent 
chlamydia, Gonorrhoea and syphilis were significant 
predictors of new HIV in four US metropolitan areas 2002-
2006 [101]. Ano-rectal Gonorrhoea is an independent risk 
factor for HIV seroconversion [102] and high rates of new 
HIV infections have been observed after ano-rectal 
Gonorrhoea [98]. Also chlamydia has been associated to 
HIV infection [103]. HIV positive MSM have a greater STI 
burden, especially urethral Gonorrhoea and syphilis and are 
more often asymptomatic as compared to HIV negative 
MSM. A Californian study found a baseline prevalence of 
STIs of 14% and an annual incidence of 21 cases per 100 
person years in asymptomatic HIV positive MSM [104]. 
DISCUSSION 
 Prompt testing, counselling, diagnosing and treatment of 
STIs are extremely important in a comprehensive HIV 
prevention strategy among MSM [60]. A visit at an STI 
clinic is also an excellent opportunity for the nurse or 
physician to discuss safer sex practices and to update the 
client of the current local STI situation and the importance of 
STIs, especially rectal infections and syphilis for HIV 
transmission [21, 98]. 
 HIV testing/counselling (traditional or rapid test) should 
always be suggested since it is crucial that HIV infected 
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individuals become aware of their infection as soon as 
possible after being infected. We have had excellent 
experience with a low-threshold rapid HIV testing program 
combined with a single structured counselling session. STIs 
are important cofactors for HIV transmission and markers of 
unprotected sex. A sexual history obtained in the clinical 
setting is often unreliable, and a standard testing procedure 
has many advantages over symptom-driven testing [104]. 
This is regardless of whether the patient seeks for localized 
symptoms or a general check-up. Since co-infections are 
common, a standardized testing regime including all 
infections at all locations is necessary. It is crucial to 
encourage all nurses and physicians engaged in the health 
care of MSM to follow guidelines for STI screening [104]. 
Gonorrhoea and chlamydia testing (with the methods as 
recommended by the local lab) should be carried out from 
the oral cavity (tonsillar and pharyngeal, respectively), the 
urethra/urine and the anal canal. Since lubricants have a mild 
bacteriostatic effect, it is important to use a technique 
minimising lubrication prior to testing, either blindly or 
under direct vision through the anoscope [40]. Rectal 
examination with anal inspection and digital palpation is an 
excellent and simple method to detect warts, ulcers and 
tumours. Positive rectal chlamydia samples should be sent to 
a specialist lab for LGV sequencing. Blood should be tested 
for syphilis, Hepatitis A, B (in non-immune subjects) and C 
and HIV. Patients that are contact traced and/or partner 
notified for one infection should always be tested also for the 
other infections since different STIs very often co-occur in 
this group. Hepatitis A and B vaccination should always be 
suggested in non-immune subjects. Annual routine STI 
screening including HIV testing is recommended for all 
sexually active MSM [105]. Screening every 3-6 months has 
been advised for those at highest risk i.e. men with multiple 
partners, those using alcohol and drugs in conjunction with 
sex and those travelling to high risk cities for sex encounters. 
Sexually active HIV-positive MSM should have an STI 
screening including rectal palpation and anoscopy at least 
annually. We think that there is a strong need for specialist 
departments aimed at MSM where patients can feel secure, 
with a team that is up to date on the continuously changing 
STI epidemic situation. In such an environment important 
data can be collected and research stimulated. 
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